Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

INCA033989: the first shot on goal for MPNs?

Blood - 28 Nov 2024

Benlabiod Camelia, Psaila Bethan

Abstract excerpt

ABSTRACT: In this issue of Blood, Reis et al1 identify a monoclonal antibody, INCA033989, that selectively targets mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs), inhibiting its oncogenic activity without affecting normal hematopoiesis.

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal
Calreticulin
Mutation
Myeloproliferative Disorders

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39607716
DOI: 10.1182/blood.2024026811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

INCA033989: the first shot on goal for MPNs?PMID 39607716Read ↗

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN.Semantic proximity Read ↗

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)Semantic proximity Read ↗

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Semantic proximity Read ↗

Mutant calreticulin in myeloproliferative neoplasmsSemantic proximity Read ↗

Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibody.Semantic proximity Read ↗

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Semantic proximity Read ↗

Antibody targeting of mutant calreticulin in myeloproliferative neoplasms.Semantic proximity Read ↗

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosisSemantic proximity Read ↗

Calreticulin mutations in myeloproliferative neoplasms.Semantic proximity Read ↗

A Murine Bispecific Antibody Efficiently Redirects T Cells Against Calr Mutated Stem Cells In Vivo.Semantic proximity Read ↗

Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.